AstraZeneca shareholders vote in favour of Alexion acquisition

LONDON: A requisite majority of AstraZeneca (LON: AZN) shareholders has approved the proposal to acquire the entire common stock of Alexion Pharmaceuticals Inc., a news release said.

AstraZeneca (LON: AZN) continues to expect the acquisition will close in Q3 2021, subject to approval by Alexion shareholders, certain regulatory approvals, and other customary closing conditions.

The acquisition was described in a circular to shareholders on 12 April 2021. The resolution was set out in the Company’s notice of general meeting and voted on by way of a poll. The results are set out below.

Pascal Soriot, Chief Executive Officer, said: “The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion’s leadership in complement biology and rare diseases with AstraZeneca’s expertise in precision medicine and growing presence in immunology. We look forward to together advancing life-changing science and bringing even more medicines to patients globally.”

AstraZeneca plc LON: AZN

Share price

7,590.00 GBX −127.00 (1.65%)

11 May, 2:00 pm GMT+1 · Disclaimer

www.astrazeneca.com

Leave a Reply

Your email address will not be published. Required fields are marked *